Pre-eclampsia primary prevention

Jump to navigation Jump to search

Pre-eclampsia Microchapters


Patient Information


Historical Perspective




Differentiating Pre-eclampsia from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pre-eclampsia primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Pre-eclampsia primary prevention

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pre-eclampsia primary prevention

CDC on Pre-eclampsia primary prevention

Pre-eclampsia primary prevention in the news

Blogs on Pre-eclampsia primary prevention

Directions to Hospitals Treating Pre-eclampsia

Risk calculators and risk factors for Pre-eclampsia primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Zand, M.D.[2]


Primary prevention

Indications of asprin prophylactic use in pregnancy


Risk level Risk factors Recommendation
High risk *Previous preeclampsia

erythematosus, antiphospholipid syndrome)

Starting low dose of asprin if the patient has one or more of these risk factors


  • Sociodemographic characteristics (African

American race, low socioeconomic status)

  • Age≥ 35 years old
  • Previous history factors of:
Starting low-dose aspirin if the patient has

two or more of these moderate-risk factors

Low risk Previous uncomplicated full term delivery NO recommended aspirin


  1. Hofmeyr, G Justus; Lawrie, Theresa A; Atallah, Álvaro N; Torloni, Maria Regina (2018). "Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD001059.pub5. ISSN 1465-1858.
  2. Rolnik, Daniel L.; Wright, David; Poon, Liona C.; O’Gorman, Neil; Syngelaki, Argyro; de Paco Matallana, Catalina; Akolekar, Ranjit; Cicero, Simona; Janga, Deepa; Singh, Mandeep; Molina, Francisca S.; Persico, Nicola; Jani, Jacques C.; Plasencia, Walter; Papaioannou, George; Tenenbau Gavish, Kinneret; Meiri, Hamutal; Gizurarson, Sveinbjorn; Maclagan, Kate; Nicolaides, Kypros H. (2017). "Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia". New England Journal of Medicine. 377 (7): 613–622. doi:10.1056/NEJMoa1704559. ISSN 0028-4793.
  3. Mayrink, J.; Costa, M. L.; Cecatti, J. G. (2018). "Preeclampsia in 2018: Revisiting Concepts, Physiopathology, and Prediction". The Scientific World Journal. 2018: 1–9. doi:10.1155/2018/6268276. ISSN 2356-6140.
  4. Rumbold A, Duley L, Crowther CA, Haslam RR (January 2008). "Antioxidants for preventing pre-eclampsia". Cochrane Database Syst Rev (1): CD004227. doi:10.1002/14651858.CD004227.pub3. PMC 6718237 Check |pmc= value (help). PMID 18254042.
  5. Ostadrahimi, Alireza; Mohammad-Alizadeh, Sakineh; Mirgafourvand, Mozhgan; Yaghoubi, Sina; Shahrisa, Elham; Farshbaf-Khalili, Azizeh (2016). "Effects of Fish Oil Supplementation on Gestational Diabetes Mellitus (GDM): A Systematic Review". Iranian Red Crescent Medical Journal. 18 (11). doi:10.5812/ircmj.24690. ISSN 2074-1804.
  6. . doi:10.1097/AOG.0000000000003891. Check |doi= value (help). Missing or empty |title= (help)